Aerothionin
目录号 : GC15759
An antimycobacterial compound derived from marine sponges
Cas No.:28714-26-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 29 μM for HeLa cells proliferation
Aerothionin is derived from marine sponges with an antimycobacterial activity.
Antimycobacterial drugs are used in the treatment of diseases caused by Mycobacterium genus, such as tuberculosis and leprosy.
In vitro: In a continuation of efforts to identify bioactive compounds from Red Sea Verongid sponges, the organic extract of the sponge Suberea species afforded seven compounds including aerothionin, together with two new dibrominated alkaloids and four known compounds. In-vitro cytotoxicity study showed that aerothionin and subereaphenol C had potent cytotoxic activity against HeLa cell line with IC50 values of 29 and 13.3 μM, respectively. [1].
In vivo: Red Sea Suberea mollis sponge extract (SMSE), which contains aerothionin, was evaluated for its protective effect on carbon tetrachloride- (CCl4-) induced acute liver injury in rats. Rats were orally administered three different concentrations of SMSE along with CCl4 for 14 days. SMSE could significantly reduce liver enzyme activities and hepatic MDA formation. In addition, SMSE was able to restore NO, SOD, GSH, GPx, and CAT. The histopathological results further confirmed these in-vivo findings [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Shaala, L. A.,Youssef, D.T.A.,Badr, J.M., et al. Bioactive secondary metabolites from the read sea marine verongid sponge Suberea species. Mar.Drugs 13, 1621-1631 (2015).
[2] Abbas AT, El-Shitany NA, Shaala LA, Ali SS, Azhar EI, Abdel-Dayem UA, Youssef DT. Red Sea Suberea mollis Sponge Extract Protects against CCl4-Induced Acute Liver Injury in Rats via an Antioxidant Mechanism. Evid Based Complement Alternat Med. 2014;2014:745606.
| Cas No. | 28714-26-3 | SDF | |
| 化学名 | (5S,5'S,10R,10'R)-N,N'-1,4-butanediylbis[7,9-dibromo-10-hydroxy-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,6,8-triene-3-carboxamide | ||
| Canonical SMILES | O=C(NCCCCNC(C1=NO[C@@]2([C@@H](O)C(Br)=C(OC)C(Br)=C2)C1)=O)C3=NO[C@@]4([C@@H](O)C(Br)=C(OC)C(Br)=C4)C3 | ||
| 分子式 | C24H26Br4N4O8 | 分子量 | 818.1 |
| 溶解度 | Soluble in ethanol;Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2223 mL | 6.1117 mL | 12.2234 mL |
| 5 mM | 0.2445 mL | 1.2223 mL | 2.4447 mL |
| 10 mM | 0.1222 mL | 0.6112 mL | 1.2223 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet